Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.9000 (1.28%) ($7.9000 - $7.9000) on Tue. Mar. 15, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.48% (three month average) | RSI | 37 | Latest Price | $7.9000(1.28%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.5% a day on average for past five trading days. | Weekly Trend | TGTX declines -7.1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(77%) ARKG(72%) IBB(69%) ARKK(66%) IBUY(61%) | Factors Impacting TGTX price | TGTX will decline at least -3.74% in a week (0% probabilities). VIXM(-49%) VXX(-42%) UUP(-25%) TBT(-15%) EDOC(-10%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.74% (StdDev 7.48%) | Hourly BBV | -0.9 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-10.01(-226.71%) | Resistance Level | $9.5 | 5 Day Moving Average | $8.52(-7.28%) | 10 Day Moving Average | $8.79(-10.13%) | 20 Day Moving Average | $9.5(-16.84%) | To recent high | -61.4% | To recent low | 1.3% | Market Cap | $1.001b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |